5 completed, 1 recruiting, 1 terminated. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Surface-Active Agents: new trials by email Literature Review of Surface-Active Agents trials Research Report on Surface-Active Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) - Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1 / Phase 2 | Recruiting | enGene, Inc. | 350 | 2021-04-22 | 2026-08-07 |
| London's Exogenous Surfactant Study for COVID19 Bovine Lipid Extract Surfactant - ARDS, Human, COVID-19 | Phase 1 / Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 20 | 2020-11-23 | 2021-11-11 |
| Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy Curosurf, Sham - Congenital Heart Disease, Hypoplastic Left Heart Syndrome | Phase 1 | Terminated | University of Michigan | 2 | 2020-02-25 | 2023-09-13 |
| Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin Surfactants, Saline Solution - Skin and Connective Tissue Diseases | Phase 1 | Completed | Prof. Dr. Dr. Ursula Mirastschijski | 24 | 2016-12-08 | 2017-09-07 |
| Aerosolized Surfactant in Neonatal RDS Surfactant - Respiratory Distress Syndrome, Newborn | Phase 1 / Phase 2 | Completed | Sood, Beena G., MD, MS | 159 | 2014-12-01 | 2021-08-25 |
| Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients. Curcumin, LED, Surfactant - Dentist-Patient Relations | Phase 1 | Completed | University of Sao Paulo | 24 | 2014-01-01 | 2015-01-13 |
| First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome synthetic surfactant (CHF5633) - Respiratory Distress Syndrome in Premature Infants | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 40 | 2012-10-01 | 2020-07-31 |
Respiratory Distress Syndrome (2) · COVID-19 (1) · Carcinoma in Situ (1) · Heart Defects, Congenital (1) · Hypoplastic Left Heart Syndrome (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Respiratory Distress Syndrome In Premature Infants (1) · Respiratory Distress Syndrome, Newborn (1) · Skin and Connective Tissue Diseases (1) · Urinary Bladder Neoplasms (1)
Chiesi Farmaceutici S.p.A. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Prof. Dr. Dr. Ursula Mirastschijski (1) · Sood, Beena G., MD, MS (1) · University of Michigan (1) · University of Sao Paulo (1) · enGene, Inc. (1)
United States (3) · Canada (2) · Germany (2) · United Kingdom (2) · Australia (1) · Brazil (1) · France (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1)
Beena G. Sood, MD, MS (1) · Christian Speer, MD (1) · Christine Tosone, Ms, RAC (1) · Jim Lewis, MD (1) · Steven Donn, MD (1) · Ursula Mirastschijski, Prof. Dr. (1)
PMID 24703280, PMID 28465315, PMID 33338661
2015 (1)